IQuity, Inc., a specialty diagnostic technology company, announced today that Don Hardison has been appointed to its Board of Directors. Hardison is an executive with extensive experience as CEO, COO, and Board Director for emerging private, public, and Fortune 500 companies within the molecular, clinical diagnostic, and medical device industries. He also has extensive marketing and sales experience within the pharmaceutical industry. His operational and commercial expertise in both private and public fundraising, strategy development, team-building, and go-to-market, along with expertise in complex healthcare reimbursement framework and processes brings significant value to IQuity.
Click to Tweet: “Great news that Don Hardison is joining the IQuity Board.” #AutoimmuneDisease #endMS
Mr. Hardison was most recently the President, CEO, and board member of Good Start Genetics from April 2010 to March this year. For over 30 years, Mr. Hardison has held a number of executive and senior management positions at companies including Laboratory Corporation of America, or LabCorp, a clinical laboratory company, Exact Sciences Corporation, a molecular diagnostic company, Quest Diagnostics Inc., a clinical laboratory company and others. He also has served on the boards of directors of several private and public companies throughout his distinguished career.
“We are pleased that Don has accepted our invitation to join the IQuity Board,” said Chase Spurlock, PhD, Chief Executive Officer. “Don’s deep experience in diagnostic laboratory management will be invaluable as we prepare to launch our novel tests that address unmet needs of the millions of patients looking for answers when they have symptoms that appear to be autoimmune related, such as multiple sclerosis or inflammatory bowel disease.”
“I am excited to work with the IQuity management team and the other board members as they continue their mission to build a valuable company through developing and providing accurate, actionable, RNA-based information for physicians to diagnose autoimmune disease quicker and earlier in the disease progression than ever before, and to ultimately provide the best treatment for their patients,” Hardison said.
IQuity is a specialty diagnostic technology company leveraging machine learning methods to deliver breakthrough RNA analytics across neurology, gastroenterology and rheumatology. The accuracy of these methods at the earliest onset of symptoms exceeds 90% and offers providers the ability to shorten the diagnostic process for autoimmune disease and related conditions. IQuity will perform the tests in its CLIA-certified laboratory and report the result to providers in as little as 7 days.
CISION PR Newswire